Irinotecan

• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke… Pending
  2024-514682-19-00 Phase III 2 countries Universitaetsklinikum Heidelberg AöR
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 Phase I/II 10 countries The University Of Birmingham
• Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test Pending
  2025-521045-24-00 Phase III 2 countries Unicancer
• A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending
  2025-521209-42-00 Phase IV 3 countries Fondazione GONO G.I.
• Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending
  2025-522377-12-00 Phase III 1 country Charite Universitaetsmedizin Berlin KöR
• Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending
  2025-522431-34-00 Phase II 1 country Region Hovedstaden
• LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and… Recruiting
  2023-508995-12-01 Phase II 4 countries Novartis Pharma AG
• Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed… Recruiting
  2024-512484-31-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed b… Recruiting
  2024-518143-38-00 Phase II/III 1 country Fondation Franc.Cancerologie Digestive
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
• ROMANCE Recruiting
  2025-521319-38-00 Phase II 1 country Gruppo Oncologico Dell'Italia Meridionale
• PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai… Recruiting
  2025-522108-26-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
• Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line … Recruiting
  2024-517766-41-00 Phase II 1 country Association Gercor
• Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with… Recruiting
  2024-519048-33-00 Phase II/III 1 country Centre Hospitalier Universitaire Rouen
• Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting
  2025-520694-39-00 Phase II 1 country Unicancer
• Efficacy and safety of trifluridin/tipiracil in combination with nanoliposomal irinotecan as a second line therapy in patients with cholangi… Recruiting
  2024-517330-18-00 Phase II 1 country Heinrich-Heine-Universitaet Duesseldorf
• CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met… Recruiting
  2024-519322-20-00 Phase III 2 countries Gruppo Oncologico Dell'Italia Meridionale
• metastatic colorectal cancer Recruiting
  2023-504831-42-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours Recruiting
  2023-504246-64-02 Phase I/II 1 country Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron
• Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting
  2023-508076-11-00 Phase III 1 country Charite Universitaetsmedizin Berlin KöR
• A study of AZD0901 alone or in combination with other anticancer drugs in patients with advanced/metastatic cancer. Recruiting
  2023-508275-37-00 Phase I/II 2 countries AstraZeneca AB
• A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting
  2023-509851-15-00 Phase III 3 countries Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
• PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge… Recruiting
  2024-511070-68-01 Phase III 1 country Centre Hospitalier Universitaire De Dijon
• Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting
  2023-505298-34-00 Phase II 1 country Unicancer

Showing 1–24 of 57 trials